Full Press Release Details
Material Change Report
Aurinia Pharmaceuticals Inc. (the Company )
#1203-4464 Markham Street
Victoria, BC V8Z 7X8
News releases were issued and disseminated by the Company through Business News Wire on December 9, 2019 and
On December 9, 2019, the Company announced it had commenced a registered underwritten public offering of its common shares (the
Offering ). On December 9, 2019, the Company further announced the pricing of the Offering of 11,115,165 common shares at a public price of US$15.00 per share. The Company granted the Underwriters (defined below) an option
exercisable, in whole or in part, in the sole discretion of the Underwriters, to purchase 1,667,274 additional shares, for a period of up to 30 days (the Option ). The Option was exercised in full.
Jefferies LLC and SVB Leerink LLC acted as joint book-running managers for the Offering. H.C. Wainwright & Co. LLC,
Oppenheimer & Co. Inc., and Bloom Burton Securities Inc. acted as co-managers for the Offering (collectively, the Underwriters ).
On December 9, 2019, the Company announced it had commenced the Offering. On December 9, 2019, the Company further announced the
pricing of the Offering of 11,115,165 common shares at a public price of US$15.00 per share. The Company granted the Underwriters the Option exercisable, in whole or in part, in the sole discretion of the Underwriters, to purchase 1,667,274
additional shares, for a period of up to 30 days. The Option was exercised in full.
Jefferies LLC and SVB Leerink LLC acted as joint
book-running managers for the Offering. H.C. Wainwright & Co. LLC, Oppenheimer & Co. Inc., and Bloom Burton Securities Inc. acted as co-managers for the Offering.
The Offering closed on December 12, 2019. The shares were sold at a public offering price of US$15.00 per share. The gross proceeds to the
Company from this Offering were approximately US$191.7 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
The Company intends to use the net proceeds of the Offering for pre-commercialization and launch activities, as well as working capital and general corporate purposes.
No significant facts remain confidential in, and no information has been omitted from, this report.
For further information, please contact:
Mr. Michael R. Martin, Chief Operating Officer